Moderna

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Pfizer and BioNTech's LP.8.1-adapted COMIRNATY vaccine targeting XFG and NB.1.8.1 variants.

Absci Corporation completed a $50 million public offering of 16.67 million shares at $3.00 per share to fund its AI-powered drug discovery programs and internal pipeline development.

A Turkish study of 64 patients found measurable corneal changes 75 days after receiving two doses of the Pfizer-BioNTech COVID-19 vaccine, including 2% increased thickness and 8% reduced endothelial cell density.

Moderna has canceled plans to build an mRNA vaccine manufacturing plant at Shonan Health Innovation Park in Kanagawa Prefecture due to weak global vaccine demand and challenging business conditions.

Wacker Chemie has opened a new Biotechnology Center in Munich with space for 90 employees and state-of-the-art equipment to concentrate and intensify biotech research activities.

Sartorius Stedim Biotech and Sensible Biotechnologies have signed a Memorandum of Understanding to advance the industrialization of Sensible's first-in-class cell-based mRNA manufacturing platform.

Applied DNA Sciences implemented a 27% workforce reduction and ceased operations at Applied DNA Clinical Labs to focus exclusively on its synthetic DNA manufacturing subsidiary LineaRx.

Laverock Therapeutics has expanded its seed funding round to more than £20 million, with the latest £6.5 million extension led by Calculus Capital and including participation from Eli Lilly and Company.

Researchers developed liposomal lipid nanoparticles (LNPs) with high bilayer lipid content that exhibit enhanced mRNA encapsulation and transfection potency compared to conventional Onpattro-like formulations.

The newly appointed Advisory Committee on Immunization Practices (ACIP) voted 5-1 to recommend thimerosal-free influenza vaccines for all age groups, despite the preservative being present in only 6% of U.S. flu vaccines.